Evidence map›Paper›PMID 25914477›Full record

Observational studyWorld journal of gastroenterology2015

Epstein-Barr virus is related with 5-aminosalicylic acid, tonsillectomy, and CD19(+) cells in Crohn's disease.

Juan C Andreu-Ballester, Rafael Gil-Borrás, Carlos García-Ballesteros, Ignacio Catalán-Serra, Victoria Amigo, Virgina Fernández-Fígares, Carmen Cuéllar

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Juan C Andreu-BallesterJuan C Andreu-Ballester, Carlos García-Ballesteros, Research Department, Arnau de Vilanova Hospital, 46015 Valencia, Spain.
Rafael Gil-BorrásJuan C Andreu-Ballester, Carlos García-Ballesteros, Research Department, Arnau de Vilanova Hospital, 46015 Valencia, Spain.
Carlos García-BallesterosJuan C Andreu-Ballester, Carlos García-Ballesteros, Research Department, Arnau de Vilanova Hospital, 46015 Valencia, Spain.
Ignacio Catalán-SerraJuan C Andreu-Ballester, Carlos García-Ballesteros, Research Department, Arnau de Vilanova Hospital, 46015 Valencia, Spain.
Victoria AmigoJuan C Andreu-Ballester, Carlos García-Ballesteros, Research Department, Arnau de Vilanova Hospital, 46015 Valencia, Spain.
Virgina Fernández-FígaresJuan C Andreu-Ballester, Carlos García-Ballesteros, Research Department, Arnau de Vilanova Hospital, 46015 Valencia, Spain.
Carmen CuéllarJuan C Andreu-Ballester, Carlos García-Ballesteros, Research Department, Arnau de Vilanova Hospital, 46015 Valencia, Spain.
Hospital Arnau de Vilanova · ESUniversidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo study anti-Epstein-Barr virus (EBV) IgG antibodies in Crohn's disease in relation to treatment, immune cells, and prior tonsillectomy/appendectomy.

methodsThis study included 36 CD patients and 36 healthy individuals (controls), and evaluated different clinical scenarios (new patient, remission and active disease), previous mucosa-associated lymphoid tissue removal (tonsillectomy and appendectomy) and therapeutic regimens (5-aminosalicylic acid, azathioprine, anti-tumor necrosis factor, antibiotics, and corticosteroids). T and B cells subsets in peripheral blood were analyzed by flow cytometry (markers included: CD45, CD4, CD8, CD3, CD19, CD56, CD2, CD3, TCRαβ and TCRγδ) to relate with the levels of anti-EBV IgG antibodies, determined by enzyme-linked immunosorbent assay.

resultsThe lowest anti-EBV IgG levels were observed in the group of patients that were not in a specific treatment (95.4 ± 53.9 U/mL vs 131.5 ± 46.2 U/mL, P = 0.038). The patients that were treated with 5-aminosalicylic acid showed the highest anti-EBV IgG values (144.3 U/mL vs 102.6 U/mL, P = 0.045). CD19(+) cells had the largest decrease in the group of CD patients that received treatment (138.6 vs 223.9, P = 0.022). The analysis of anti-EBV IgG with respect to the presence or absence of tonsillectomy showed the highest values in the tonsillectomy group of CD patients (169.2 ± 20.7 U/mL vs 106.1 ± 50.3 U/mL, P = 0.002). However, in the group of healthy controls, no differences were seen between those who had been tonsillectomized and subjects who had not been operated on (134.0 ± 52.5 U/mL vs 127.7 ± 48.1 U/mL, P = 0.523).

conclusionHigh anti-EBV IgG levels in CD are associated with 5-aminosalicylic acid treatment, tonsillectomy, and decrease of CD19(+) cells.

Indexed as

TonsillectomyAdultAntibodies, ViralAntigens, CD19Anti-Inflammatory AgentsBiomarkersCrohn DiseaseFemaleHerpesvirus 4, HumanHumansImmunoglobulin MLymphocytesMaleMesalamineMiddle AgedPredictive Value of TestsAntibodies, ViralAntigens, CD19Anti-Inflammatory AgentsBiomarkersImmunoglobulin MMesalamine5-aminosalicylic acidB cellsCrohn’s diseaseEpstein-Barr virusTonsillectomy

Identifiers

PMID25914477
PMCPMC4402315
OpenAlexW2411075808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.